The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects

Therapeutic Advances in Respiratory Disease

Volumn 7, Issue 6, 2013, Pages 311-319

  Feldman, Gregory J ^a   Edin, Anton ^b  

^a Research South Carolina Pharmaceutical Research   (United States)

^b Alliance Biomedical Russian Group   (Russian Federation)

Author keywords

COPD; LAMA and LABA combination; UMEC VI; Umeclidinium; Vilanterol

Indexed keywords

INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SYMPTOM;

COPD; LAMA AND LABA COMBINATION; UMEC/VI; UMECLIDINIUM; VILANTEROL;

BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX;

EID: 84887847824     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465813499789     Document Type: Article

References (40)

1. Anzueto A. Decramer M. Kaelin T. Richard N. Taberrer M. Harris S. (2013) The efficacy and safety of umeclidinium/vilanterol compared with tiotropium in COPD. In: American Thoracic Society Congress, Philadelphia, PA, 2013, poster 42837.
2. Anzueto A. Sethi S. Martinez F.J. (2007) Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4: 554–564.
3. Beeh K. Beier J. (2009) Indacaterol: a new once daily long-acting beta2 agonist. Int J Chron Obstruct Pulmon Dis 4: 37–41.
4. Belkonte K.E. (2005) Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 297–304.
5. Bourbeau J. Bartlett S.J. (2008) Patient adherence in COPD. Thorax 63: 831–838.
6. Cazzola M. Calzetta L. Matera M. (2011) β2-adrenoreceptor agonists: current and future direction. Br J Pharmacol 163: 4–17.
7. Cazzola M. Molimard M.G. (2010) The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23: 257–267.
8. Cazzola M. Page C.P. Rogliani P. Matera M.G. (2013) β2-agonist therapy in lung disease. Am J Respir Crit Care Med 187: 690–696.
9. Cazzola M. Tashkin D.P. (2009) Combination of tiotropium and formoterol in the treatment of COPD: effect on lung function. COPD 6: 404–415.
10. Cazzola M. Testi R. Matera M.G. (2002) Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 41: 19–30.
11. Celli B. Crater G. Kilbride S. Mehta R. Tabberer M. Kalberg C. (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in patients with COPD. American Thoracic Society Congress, Philadelphia, PA, 2013, poster 39941.
12. Decramer M. Maltais F. Feldman G. Brooks J. Harris S. Mehta R. (2013) Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 185: 393–399.
13. Domingo C. (2013) Ultra-LAMA, ultra-LABA, ultra-inhaled steroids? The future has landed. Arch Bronchopneumol. Available at: http://www.elsevier.es/sites/default/files/elsevier/eop/S1579-2129(13)00042-6.pdf ( accessed May 2013).
14. Donohue J.F. Maleki-Yazdi M.R. Kilbride S. Mehta R. Kalberg C. Church A. (2013) Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in patients with COPD. Respir Med, (Also Poster 42583.) American Thoracic Society Congress, 2013; Philadelphia, PA.
15. Feldman G. Walker R.R. Brooks J. Mehta R. Crater G. (2012) 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial. Pulm Pharmacol Ther 25: 465–471.
16. GlaxoSmithKline (2012a) GlaxoSmithKline Trials Registry: Umeclidinium/Vilanterol and Umeclidinium, Study number DB2113359. Available at: http://download.gsk-clinicalstudyregister.com/files/0e8427f4-980f-458c-8b23-37580dd0abaf ( accessed May 2013).
17. GlaxoSmithKline (2012b) GlaxoSmithKline Trials Registry: GSK573719 (umeclidinium bromide), GW642444 (vilanterol), tiotropium, Study number DB2113374. Available at: http://download.gsk-clinicalstudyregister.com/files/9adb56ec-8919-47dd-be40-e0f906298852 ( accessed June 2013).
18. GlaxoSmithKline (2012c) GlaxoSmithKline Trials Registry:, Study number DB2116844. Available at: http://download.gsk-clinicalstudyregister.com/files/1f37e00a-6090-4648-9a79-4e49e481af40
19. GOLD (2013) Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. Available at: http://www.goldcopd.org/guidelinesglobal-strategy-for-diagnosis-management.pdf ( accessed May 2013).
20. Hanania N.A. Marciniuk D. (2011) A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest 140: 565–566.
21. Jones P.W. Quirk F.H. Baveystock C.M. (1991) The St George's Respiratory Questionnaire. Respir Med 85(Suppl. B): 25–31.
22. Kerwin E. Scott-Wilson C. Sanford L. Rennard S. Agusti A. Barnes N. (2013) A randomized trial of fluticasone/furoate/vilanterol (50/25 mcg; 100/25 mcg) on lung function in COPD. Respir Med 107: 560–569.
23. Krigsman K. Nilsson J.L. Ring L. (2007) Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected refill prescriptions. Pharmacoepidemiol Drug Saf 16: 441–448.
24. Mahler D.A. D–Urzo A. Bateman E.D. Ozkan S.A. White T. Peckitt C. (2012) Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone. Thorax 67: 781–788.
25. Mousseau M. (2011) Overview of Main Changes in GOLD Guidelines 2011. Available at: http://www.imt.ie/mims/2013/02/overview-of-main-changes-in-gold-guidelines-2011.html ( accessed June 2013).
26. O–Donnell D.E. Fluge T. Gerken F. Hamilton A. Webb K. Aguilaniu B. (2004) Effects of tiotropium on lung hyperinflation, dispnoea and exercise tolerance in COPD. Eur Respir J 23: 832–840.
27. O–Donnell D.E. Lavenisiana P. (2006) Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev 100: 61–67.
28. Procopiou P.A. Barrett V.J. Bevan N.J. Biggadike K. Box P.C. Butchers P.R. (2010) Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 53: 4522–4530.
29. Restrepo R.D. Alvarez M.T. Wittnebel L.D. Sorenson H. Wettstein R. Vines D.L. (2008) Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 3: 371–384.
30. Rodrigo G.J. Neffen H. (2012) Comparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic review. Chest 142: 1104–1110.
31. Salmon M. Luttman M.A. Foley J.J. Buckley P.T. Schmidt D.B. Burman M. (2013) Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 345: 260–270.
32. Tashkin D. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S., for the UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543–1554.
33. Tashkin D.P. Ferguson G.T. (2013) Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 14: 49.
34. Tashkin D. Kesten S. (2003) Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 123: 1441–1449.
35. Toy E.L. Beaulieu N.U. McHale J.M. Welland T.R. Plausechinat C.A. Swensen A. (2011) Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 105: 435–441.
36. Triverdi R. Richard N. Mehta R. Church A. (2013) Efficacy and safety of umeclidinium monotherapy once-daily in patients with chronic obstructive pulmonary disease. American Thoracic Society Congress Philadelphia, PA, 2013, poster 811.
37. Short P.M Williamson P.A Douglas H. Elder J. Lipworth S.I.W Schembri S. Lipworth B.G. The impact of Tiotropium on Mortality and Exacerbations When Added to Inhaled Corticosteroids and Long-acting B-Agonists Therapy in COPD. Chest 2012; 141(1): 81–86.
38. Van Der Molen T. Cazzola M. (2012) Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centered outcomes. Prim Care Respir J 21: 101–108.
39. Van Noord J. Aumann J.L. Janssens E. Smeets J. Verhaert J. Disse B. (2005) Comparison of tiotropium once daily, formoterol twice daily, and both combined once daily in patients with COPD. Eur Respir J 26: 214–222.
40. Van Noord J.A. Aumann J.L. Janssens E. Verhaert J.J. Smeets J. Mueller A. (2006) Effects of tiotropium with or without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 129: 509–517.